1. Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma 
Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice Davis-Sproul, Nilanjan Ghosh, Heather Symons, Javier Bolaños-Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder 
Biology of Blood and Marrow Transplantation 
Volume 19, Issue 4, Pages (April 2013)
DOI: /j.bbmt
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Kaplan-Meier survival estimates. (A) PFS (dashed line) and OS (solid line) for all patients (n = 44). (B) PFS, stratified by remission. Patients receiving alloBMT in first remission (n = 21, solid line) compared with patients receiving alloBMT beyond first remission (n = 23, dashed line), P = .08. (C) PFS (dashed line) and OS (solid line) for patients receiving MAC (n = 20). (D) PFS (dashed line) and OS (solid line) for patients receiving RIC (n = 24).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Cumulative incidence of relapse and nonrelapse mortality for RIC (n = 24, solid lines) and MAC (n = 20, dashed lines) alloBMT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions